✦ LIBER ✦

231 Efficacy of VEGFR2 targeted mAb therapy in preclinical cancer models resistant to antiangiogenic therapy

✍ Scribed by D. Surguladze; M.J. Plym; J. Malaby; M. Prewett; M. Rutstein; J. Schwartz; D. Lu; L. Witte; J.R. Tonra

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

34 Efficacy of VEGFR2 Targeted mAb Thera

✍ Surguladze, D.; Malaby, J.; Prewett, M.; Duignan, I.; Rutstein, M.; Yao, Y.M.; S 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 55 KB

375 Dual PI3K/mTOR and HER2 Blockade Res

✍ De, P.; Sun, Y.; Dey, N.; Leyland-Jones, B. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 76 KB

Mechanisms of Disease: understanding res

✍ Nahta, Rita; Yu, Dihua; Hung, Mien-Chie; Hortobagyi, Gabriel N; Esteva, Francisc 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 349 KB

804 Dual MTORC1/2 and HER2 Blockade Resu

✍ C. Garcia-Garcia; Y.H. Ibrahim; V. Serra; M.T. Calvo; C. Aura; J. Pérez; C. Romm 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 51 KB

759 Xenospheres – a Preclinical Model of

✍ P. Luraghi; E. Menietti; G. Reato; F. Sassi; G. Migliardi; E. Cipriano; A. Berto 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB

The role of HER2 in early breast cancer

✍ Jaclyn A. Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagat 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 297 KB